Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY Français
- Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world -
TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive longer-term data for Pr CASGEVY ® (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy.
"This longer-term data reinforces CASGEVY's durable clinical benefits for eligible people living with sickle cell disease or transfusion-dependent beta thalassemia," said Kevin Kuo, M.D., Hematologist and Associate Professor in the Division of Hematology, University of Toronto, Clinician Investigator in the Red Blood Cell Disorders Clinic at University Health Network, and Principal Investigator for the CLIMB-131 clinical program. "These results are a reminder of what science can achieve, especially for patients and communities with significant unmet need."
New longer-term follow-up data presented from the CASGEVY trials
In SCD, 43/45 (95.6%) evaluable patients (those with at least 16 months of follow-up) were free from vaso-occlusive crises (VOCs) for at least 12 consecutive months (VF12) in CLIMB-121 and CLIMB-131 combined (95% CI: 84.9%, 99.5%). The mean duration of VOC-free was 35.0 months (range 14.4 to 66.2 months).
All evaluable patients (45/45 [100%]) achieved freedom from in-patient hospitalization for severe VOCs for at least 12 consecutive months (HF12) in CLIMB-121 and CLIMB-131 combined (95% CI: 92.1%, 100%), with a mean hospitalization-free of 36.1 months (range 14.5 to 66.2 months).
In TDT, 54/55 (98.2%) evaluable patients (those with at least 16 months of follow-up) achieved transfusion-independence for at least 12 consecutive months with a weighted average hemoglobin (Hb) of at least 9 g/dL (TI12) in CLIMB-111 and CLIMB-131 combined (95% CI: 90.3%, 100%). The mean duration of transfusion independence was 40.5 months (range 13.6 to 70.8 months).
The one evaluable patient who did not achieve TI12 has been transfusion free for 14.8 months.
Iron removal therapy has been stopped for more than 6 months in 39/56 (69.6%) treated patients following infusion with CASGEVY, with sustained improvement in ferritin and liver iron content, suggesting that CASGEVY has the potential to correct ineffective erythropoiesis.
Patients continue to demonstrate stable levels of fetal hemoglobin (HbF) and allelic editing.
The safety profile of CASGEVY continues to be generally consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant.
Progress in bringing CASGEVY to patients
Through reimbursement agreements, Vertex has secured access for eligible SCD or TDT patients in multiple countries including Austria, Bahrain, England, Denmark, the Kingdom of Saudi Arabia, Northern Ireland, Scotland, the United Arab Emirates, the United States and Wales.
In Canada, CASGEVY received positive recommendations for reimbursement from both Canadian health technology agencies between December 2024 and January 2025; however, a Letter of Engagement from the pan-Canadian Pharmaceutical Alliance (pCPA) is pending.
Vertex is continuing to work with government and reimbursement authorities globally to secure sustainable access for additional eligible patients.
About Sickle Cell Disease (SCD)
SCD is a debilitating, progressive, life-shortening genetic disease. SCD patients report health-related quality of life scores well below the general population and significant health care resource utilization. SCD affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or "sickled" red blood cells. The clinical hallmark of SCD is vaso-occlusive crises (VOCs), which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity.
About Transfusion-Dependent Beta Thalassemia (TDT)
TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT requires frequent blood transfusions and iron chelation therapy throughout a person's life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity.
About Pr CASGEVY ® (exagamglogene autotemcel)
Pr CASGEVY ® is an autologous genome edited hematopoietic stem cell-based therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate vaso-occlusive crises (VOCs) for patients with SCD and transfusion requirements for patients with TDT.
CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world.
About the CLIMB Trials
The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies in select regions for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.ca.
Vertex Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Kevin Kuo, M.D., in this press release, and statements regarding expectations for the anticipated durable clinical benefits of CASGEVY, expectations for the safety profile of CASGEVY, expectations for the Letter of Engagement from the pCPA, plans to continue working with government and reimbursement authorities globally to secure sustainable access for patients, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
Vertex Pharmaceuticals Incorporated
Media: [email protected] orCanada: +1 647-790-1600orU.S.: 617-341-6992
SOURCE Vertex Pharmaceuticals (Canada) Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Net Zero Now Clears Key Milestone on 320-Acre Energy Campus, Accelerating Alberta's Low-Carbon Data Center Infrastructure Build Out
CALGARY, AB, July 4, 2025 /CNW/ - Net Zero Now Ltd. ("Net Zero") is pleased to announce the completion of environmental studies on its first energy campus in Alberta, a 320-acre site specifically selected to meet the infrastructure requirements and locational preferences of both electricity generation and data centers. With data centers applying for 16,229MW of load capacity from the electricity grid in Alberta, and the Alberta Electric System Operator (AESO) imposing an interim large load connection limit of 1,200MW, Net Zero's energy campus is solving the most critical constraint in Canada's fastest-growing data center market: access to electricity where data centers want to operate. "As the AESO's large-load interconnection queue grew exponentially, we recognized the need for a fundamentally different approach to powering these large loads," said Scott Martin, Head of Energy at Net Zero. "We're giving hyperscale operators the ability to directly connect through a co-located energy campus, or contract with our energy campus virtually through the electricity grid in order to bring their own generation online and serve a pre-existing site." The 320-acre energy campus provides a speed-to-market and low-cost electricity supply solution that includes 400MW of base load electricity generation, power quality services, backup supply, and an accompanying data center campus, the renderings of which are pictured above. In addition to the focus on achieving a net zero carbon emission electricity supply, Net Zero will deploy net zero building techniques to reduce the embodied and operational carbon footprint of its data center structures which include: advanced insulation systems, sustainable materials, and energy-efficient construction practices. "While Alberta is not currently ranked as a top-tier global data center market, we expect that will change in the near future as investors and operators look at the favourable electricity cost, tax environment, and foreign exchange rate that comes with doing business in Alberta," said Logan Downing, Head of Carbon Strategy at Net Zero. "Many data center operators are reluctant to enter a new market due to a lack of electricity supply, local contacts, or regulatory experience. We provide fully-permitted construction-ready energy campuses that enable speed-to-market, low-cost electricity supply, and a best-in-class carbon intensity to accelerate Alberta's position in the rapidly growing AI industry." Net Zero's energy campuses will bring more electricity supply online to help keep electricity costs low for all Albertans and Alberta-based businesses, while also contributing new property tax revenue and jobs to the communities. Net Zero is pleased to see how the Alberta government has positioned itself as an attractive location for data centers by creating a stable political environment, focusing on reducing red tape, and creating pathways to establish meaningful connections with the communities and First Nations. As a result, Net Zero is also evaluating additional strategic sites across Alberta to meet the growing electricity demand from data center operators. Net Zero Now is building the infrastructure backbone of Canada's digital future. Our energy campuses enable the co-location of electricity generation and compute load, accelerating access to shovel-ready projects with low-cost electricity and net zero carbon emissions at strategic locations in Alberta.
Cision Canada
2 hours ago
- Cision Canada
/R E P E A T -- MEDIA ADVISORY - The SQDC to Extend the Opening Hours of Some Stores/ Français
MONTRÉAL, July 2, 2025 /CNW/ - The Société québécoise du cannabis invites media representatives to attend an update on its project to extend the opening hours of some stores, part of its effort to fight the illegal market as the company opens a new store in the Vieux-Montréal district. Date: Friday, July 4, 2025 Time: 9:30 a.m. Address: 84, rue Saint-Paul Est, Montréal Company representatives at the event: Suzanne Bergeron, President and Chief Executive Officer; Alexander Bove, Director, Real Estate; Jean-François Dulac-Lemelin, Senior Vice-President, Customer Experience; Théogène Morin, Regional Director; Mario Quattrociocche, Manager, Vieux-Montréal store; and Alban Troja, Director, Evolution and Performance, Customer Experience. Please note that interviews will be possible in French and English, microphone stands may be useful (no audio mult box) and parking is difficult in the area. About the Société québécoise du cannabis (SQDC) The SQDC is a government corporation mandated to distribute and sell cannabis in Québec with a focus on protecting customers' health and safety. The company is committed to offering quality products and informing and advising consumers on how to minimize the health impacts of cannabis. The goal is to shrink the illegal cannabis market in Québec. The declared dividend equal to the company's net income is transferred to the Fonds de lutte contre les dépendances, a fund managed by the Ministère des Finances du Québec, and reinvested primarily in cannabis-related education, prevention efforts and research. For more information, visit
Cision Canada
4 hours ago
- Cision Canada
MemeCore Announces $M Token Listing on Major Centralized Exchanges
SINGAPORE, July 4, 2025 /CNW/ -- MemeCore, the world's first Layer 1 blockchain built specifically for the Meme 2.0 era, is proud to announce the official listing of its native token, $M, on multiple centralized exchanges. Trading commenced on 3 July 2025, with the $M/USDT trading pair available on Binance Alpha, Kraken, Bitget, BingX, HTX and Hashkey. To commemorate this milestone, each participating exchange will be launching exclusive trading campaigns and giveaways to reward users. Full campaign details can be found on the respective exchange platforms. Redefining Memes with Layer 1 Power MemeCore was designed to usher in a new age of crypto-powered virality — Meme 2.0 — where meme coins are no longer fleeting trends, but enduring cultural and economic forces. Through a unique incentive structure that rewards content virality, on-chain activity and community participation, MemeCore enables memes to become the backbone of a new, self-sustaining blockchain economy. What is Meme 2.0? Meme 2.0 reimagines the future of meme coins — moving beyond speculative hype into a utility-driven, community-powered model. At the heart of this vision are: Proof of Meme (PoM): A first-of-its-kind consensus model that tracks and rewards viral content, project contributions, and on-chain transactions — ensuring long-term project relevance. Meme Vaults: Smart contract-based, automatically generated reward pools that power fair and transparent contributor incentives for every meme project launched on the MemeCore chain. The Role of $M $M is the utility token of the MemeCore blockchain. It powers gas fees, staking, governance, and the PoM consensus model — making it the engine behind MemeCore's viral economy. As more meme-native projects deploy on the network, demand for $M is expected to grow alongside user engagement and content creation. About MemeCore MemeCore is the first Layer 1 blockchain specially built for Meme 2.0 — a new paradigm, where meme coins evolve from short-term speculation into long-term cultural and economic forces, powered by community-driven virality. MemeCore introduces the viral economy: a Meme 2.0 paradigm where meme coins become enduring cultural assets and active economic engines. By rewarding both content virality and transaction volume, MemeCore ensures that every meaningful interaction — whether social or on-chain — becomes part of a sustainable, value-generating ecosystem.
